Abstract
Abstract Prostate cancer is a highly heritable disease that disproportionally affects African and African-American men. With this in mind, the MADCaP (Men of African Descent Carcinoma of the Prostate) Network has developed a custom genotyping platform. This array is optimized for detection of novel genetic associations in sub-Saharan African populations. The MADCaP Array contains approximately 1.6 million markers, many of which overlap the H3Africa Consortium Array and the OncoArray. It includes an imputation backbone that successfully tags 94% of common (MAF > 0.05) genetic variants in African populations (r2 threshold = 0.8). To aid in fine-mapping, the MADCaP Array has a high density of markers in genomic regions surrounding known cancer associations, including 8q24. Markers on the MADCaP Array also include over 27,000 prostate eQTLs. Using the MADCaP Array, we conducted a pilot study of 800 individuals with individual-level phenotype information. These samples include equal numbers of prostate cancer cases and controls, and they were collected from study sites in Ghana, Nigeria, Senegal, and South Africa. Here, we assess the extent to which polygenic risk scores are able to predict prostate cancer risks in African populations. We also identify non-African GWAS signals that replicate well in African populations. Additional analyses in this study include testing whether specific genetic ancestries are over-represented in cases, and quantifying the extent to which runs of homozygosity are found in the genomes of cases and controls. Citation Format: Joseph Lachance, Maxine Harlemon, Paidamoyo Kachambwa, Olabode Ajayi, Michelle Kim, Marcia Adams, Elizabeth Pugh, Lindsay Peterson, Timothy Rebbeck. Development of a custom genotyping platform and genetic prediction of prostate cancer risks in sub-Saharan Africa [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2410.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
